NCT06047262View on ClinicalTrials.gov

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

PHASE2RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Dapansutrile

Patients receive investigational product.

DRUG

Placebo

Patients receive placebo.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

Sponsors

Collaborators (1)

Olatec Therapeutics LLC

All Listed Sponsors

collaborator

European Union (Horizon Europe Programme)

UNKNOWN

collaborator

State Secretariat for Education Research and Innovation, Switzerland

OTHER

collaborator

Olatec Therapeutics LLC

INDUSTRY

lead

University Hospital, Basel, Switzerland

OTHER